Cytek Biosciences Launches New Cloud Tools and Raises Lower End of Annual Revenue Guidance

Key Facts

1Cytek Biosciences launched a new Cloud Analysis tool and a Premium subscription tier for its Cytek Cloud platform.

2Q2 2026 revenue increased by 6% to $48.10 million.

3The company raised the lower end of its full-year revenue guidance despite an increased net loss of $12.20 million.

Cytek Biosciences launched a new Cloud Analysis tool and a Premium subscription tier for its Cytek Cloud platform. AD HOC NEWS reported that the company's Q2 2026 revenue increased by 6% to $48.10 million, leading management to raise the lower end of its full-year revenue guidance despite a net loss that widened to $12.20 million.

CTKB closed at $5.81 on October 1, 2026, with the stock trading between a low of $5.75 and a high of $5.97 during that session. The expansion into digital services aims to integrate subscription-based research workflows into a platform that currently serves more than 28,000 users.